IGM Biosciences, Inc.

Equities

IGMS

US4495851085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-10 EDT			5-day change	1st Jan Change
9.34 ^USD	-7.71%		-7.25%	+12.39%

05-09	RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk	MT
05-08	Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000	MT

IGM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 13, 2023 at 04:06 pm

IGM Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 61.99 million compared to USD 58.04 million a year ago. Basic loss per share from continuing operations was USD 1.04 compared to USD 1.32 a year ago.
For the nine months, net loss was USD 185.72 million compared to USD 168.53 million a year ago. Basic loss per share from continuing operations was USD 3.73 compared to USD 4.15 a year ago.

Latest news about IGM Biosciences, Inc.

RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk	05-09	MT
Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000	05-08	MT
IGM Biosciences, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024	05-08	CI
IGM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets	04-17	MT
IGM Biosciences, Inc. Announces Refocusing of Sanofi Collaboration	04-17	CI
North American Morning Briefing : Stocks Set for -2-	03-28	DJ
HC Wainwright Adjusts IGM Biosciences Price Target to $12 From $7, Maintains Neutral Rating	03-12	MT
Earnings Flash (IGMS) IGM BIOSCIENCES Reports Q4 Revenue $651,000	03-07	MT
IGM Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-07	CI
IGM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
North American Morning Briefing : Stock Futures -2-	02-12	DJ
RBC Upgrades IGM Biosciences to Outperform From Sector Perform, Boosts Price Target to $21 From $9; Speculative Risk Kept	02-09	MT
Transcript : IGM Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 11:15 AM	01-10
North American Morning Briefing : Stock Futures -2-	12-18	DJ
BofA Securities Downgrades IGM Biosciences to Neutral From Buy, Adjusts Price Target to $8 From $20	12-15	MT
IGM Biosciences, Inc.(NasdaqGS:IGMS) dropped from NASDAQ Biotechnology Index	12-15	CI
North American Morning Briefing : Futures Pause -2-	12-08	DJ
HC Wainwright Downgrades IGM Biosciences to Neutral From Buy, Cuts Price Target to $7 From $11	12-07	MT
Wedbush Raises IGM Biosciences' PT to $20 From $16, Adjusts Downstream Funding Assumptions; Keeps Outperform Rating	12-06	MT
RBC Raises Price Target on IGM Biosciences to $9 From $8 on Reduced Ancillary Spend Amid Job Cuts, Keeps Sector Perform, Speculative Risk	12-06	MT
Medivir to Discuss Birinapant Future Following Partner's Strategic Reprioritization	12-06	MT
North American Morning Briefing : Stock Futures Rise With More Jobs Data on Tap	12-06	DJ
IGM Biosciences to Reduce Workforce by 22%, Pause Hematologic Oncology Clinical Development	12-06	MT
Igm Biosciences, Inc. to Reduce its Workforce by Approximately 22%	12-05	CI

Chart IGM Biosciences, Inc.

Duration

Period

More charts

Company Profile

IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Companyâs pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Companyâs development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - RBC Capital Markets Global Healthcare Conference - Fireside Chat

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for IGM Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.34 USD

Average target price

21.4 USD

Spread / Average Target

+129.12%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IGM BIOSCIENCES, INC.	+12.39%	551M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs